Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

JB Chemicals Net Plunges 76 Percent in Jun'07 Qtr (India)

This article was originally published in PharmAsia News

Executive Summary

Globally powerful India-based pharmaceutical company JB Chemicals & Pharmaceuticals posted a 76.40 percent net profit decline during second-quarter 2007 ending on June 30 compared to second-quarter 2006. The company's second quarter net sales rose by 4.07 percent, however, while its declining profit still came in at a positive RS 30.71 million crore. This company has worldwide distribution in over 50 countries. Its earnings per share registered at RS 0.36 in second-quarter 2007 compared to RS 1.55 during the same period last year. (Click here for more

Table

View full table

Tags:
Latest Headlines

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

Ono Buys Deciphera, Gaining A Commercial Cancer Drug And Infrastructure

See All
UsernamePublicRestriction

Register

SC066397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By